Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Julio F Marchini"'
Autor:
Rodrigo A Brandão Neto, Julio F Marchini, Lucas O Marino, Julio C G Alencar, Felippe Lazar Neto, Sabrina Ribeiro, Fernando V Salvetti, Hassan Rahhal, Luz Marina Gomez Gomez, Caue G Bueno, Carine C Faria, Victor P da Cunha, Eduardo Padrão, Irineu T Velasco, Heraldo Possolo de Souza, Emergencia USP Covid group
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0244532 (2021)
BackgroundThe first cases of coronavirus disease (COVID-19) in Brazil were diagnosed in February 2020. Our Emergency Department (ED) was designated as a COVID-19 exclusive service. We report our first 500 confirmed COVID-19 pneumonia patients.Methods
Externí odkaz:
https://doaj.org/article/ff783c68945949d284b84125a330b868
Autor:
Rodrigo A Brandão Neto, Julio F Marchini, Lucas O Marino, Julio C G Alencar, Felippe Lazar Neto, Sabrina Ribeiro, Fernando S Valente, Hassan Rahhal, Luz Marina Gomez Gomez, Caue G Bueno, Carine C Faria, Victor P da Cunha, Eduardo Padrão, Irineu T Velasco, Heraldo Possolo de Souza, Emergencia USP Covid group
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0248327 (2021)
[This corrects the article DOI: 10.1371/journal.pone.0244532.].
Externí odkaz:
https://doaj.org/article/85015d1b7e2c4685beb3485514990bcc
Autor:
André Manica, Rogério Sarmento-Leite, Clara Manfroi, La Hore Rodrigues Jr, Carlos Gottschall, Julio F Marchini, Kevin Croce
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 100, Iss 1, Pp 29-36 (2013)
FUNDAMENTO: A aspirina (Ácido Acetilsalicílico - AAS) é capaz de reduzir eventos adversos cardiovasculares em pacientes portadores de Doença Arterial Coronariana (DAC) através da inibição da atividade plaquetária. Alguns pacientes com DAC, ap
Externí odkaz:
https://doaj.org/article/7724b922d52b49b497bb2b49069d395a
Autor:
André Manica, Rogério Sarmento-Leite, Clara Manfroi, La Hore Rodrigues Jr, Carlos Gottschall, Julio F Marchini, Kevin Croce
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 100, Iss 1, Pp 29-36
FUNDAMENTO: A aspirina (Ácido Acetilsalicílico - AAS) é capaz de reduzir eventos adversos cardiovasculares em pacientes portadores de Doença Arterial Coronariana (DAC) através da inibição da atividade plaquetária. Alguns pacientes com DAC, ap
Externí odkaz:
https://doaj.org/article/0618bdaf2730486dbaa50f1a88cb0af5
Autor:
Julio F. Marchini, Andre Manica, Paulo Crestani, Jochen Dutzmann, Eduardo J. Folco, Heinz Weber, Peter Libby, Kevin Croce
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 15 (2020)
Background Activated vascular cells produce submicron prothrombotic and proinflammatory microparticle vesicles. Atherosclerotic plaques contain high levels of microparticles. Plasma microparticle levels increase during acute coronary syndromes and th
Externí odkaz:
https://doaj.org/article/4a590055fb914cb69c7c7430383fe038
Autor:
Julio F, Marchini, Wilton F, Gomes, Bruno, Moulin, Marco A, Perin, Ludmilla A R R, Oliveira, J Airton, Arruda, Valter C, Lima, Antonio A G, Lima, Paulo R A, Caramori, Cesar R, Medeiros, Mauricio R, Barbosa, Fabio S, Brito, Expedito E, Ribeiro, Pedro A, Lemos
Publikováno v:
Cardiovascular diagnosis and therapy. 4(6)
Few studies have examined the very long-term outcomes after implantation of drug-eluting stents (DES) coated with biodegradable polymers (BP). This report presents the 5-year clinical follow-up of patients treated with BP-DES in the randomized PAINT
Autor:
Sophie E. P. New, Claudia Goettsch, Masanori Aikawa, Julio F. Marchini, Manabu Shibasaki, Katsumi Yabusaki, Peter Libby, Catherine M. Shanahan, Kevin Croce, Elena Aikawa
Publikováno v:
Circulation research. 113(1)
Rationale: We previously showed that early calcification of atherosclerotic plaques associates with macrophage accumulation. Chronic renal disease and mineral imbalance accelerate calcification and the subsequent release of matrix vesicles (MVs), pre
Autor:
Julio F Marchini, Andre Manica, Jochen Dutzmann, Eduardo J Folco, Heinz Weber, Peter Libby, Kevin Croce
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 32
Background: Microparticles (MP) are submicron vesicles produced by activated or apoptotic vascular cells. Agonist proteins borne by MPs enables them to function as mediators of inflammation and thrombosis. Atherosclerotic plaques contain high levels
Prevalence of high platelet reactivity in aspirin-treated patients referred for coronary angiography
Autor:
André, Manica, Rogério, Sarmento-Leite, Clara, Manfroi, La Hore, Rodrigues, Carlos, Gottschall, Julio F, Marchini, Kevin, Croce
Publikováno v:
Arquivos brasileiros de cardiologia. 100(1)
Aspirin (ASA) reduces adverse events in coronary artery disease (CAD) patients by inhibiting platelets. Some CAD patients have high platelet reactivity (HPR) despite ASA therapy and these individuals have increased risk of adverse events.The purpose
Autor:
Andrew G. Cox, Diane C. Saunders, Peter B. Kelsey Jr., Allie A. Conway, Yevgenia Tesmenitsky, Julio F. Marchini, Kristin K. Brown, Jonathan S. Stamler, Dorothy B. Colagiovanni, Gary J. Rosenthal, Kevin J. Croce, Trista E. North, Wolfram Goessling
Publikováno v:
Cell Reports, Vol 6, Iss 1, Pp 56-69 (2014)
Toxic liver injury is a leading cause of liver failure and death because of the organ’s inability to regenerate amidst massive cell death, and few therapeutic options exist. The mechanisms coordinating damage protection and repair are poorly unders
Externí odkaz:
https://doaj.org/article/b0dbc49cf4944575a2e417e636885493